Nicotine Withdrawal and Junk Food Intake: A Study

Mar.28.2022
Nicotine Withdrawal and Junk Food Intake: A Study
Nicotine withdrawal symptoms vary and peak after 1-3 days, but psychological effects can persist. Quitting smoking often leads to increased junk food cravings.

According to a report by foreign media on March 27, 2022, it is well known that the symptoms of nicotine withdrawal vary from person to person, with some struggling more than others. However, these symptoms generally peak in the first 1-3 days of quitting smoking and gradually decrease over the course of 3-4 weeks. After this time, nicotine should be completely eliminated from one's system, but psychological effects often continue to persist.

 

When nicotine enters the bloodstream, it activates the reward and pleasure pathways in the brain by increasing the levels of dopamine, a neurotransmitter responsible for feelings of well-being. It is known to affect areas in the brain that regulate breathing, memory (enhancing it), appetite, and heart rate. The brain quickly becomes addicted to this stimulating effect.

 

Additionally, smokers often turn to smoking when socializing with friends, feeling bored, or in need of a pick-me-up. Over time, this can cause the brain to associate smoking with pleasure, making it difficult to overcome psychological withdrawal symptoms even after overcoming physical nicotine withdrawal symptoms.

 

The physical symptoms of nicotine withdrawal.

 

When the nicotine receptors in the brain are suddenly deprived of nicotine, the release of dopamine decreases. This can naturally lead to an uncomfortable sensation and a strong craving for smoking, as the body has become accustomed to the need for dopamine release. The craving for nicotine can last for 5 to 30 minutes, can be very uncomfortable, and will only subside over time or with the use of nicotine replacement therapy (NRT).

 

A recent study titled "Quitting Smoking Increases Junk Food Intake: The Role of Endogenous Opioid System" has been published in the Journal of Drug and Alcohol Dependence. The lead author of the study, Dr. Mustafa al'Absi, is a licensed psychologist and professor in the Department of Family Medicine and Bio-behavioral Health at the University of Minnesota Medical School. His team researched the brain functions responsible for addiction and appetite regulation, specifically examining the potential preference for junk food during nicotine withdrawal.

 

Researchers studied a group of smoking and non-smoking participants between the ages of 18 and 75. They were randomly assigned to quit using nicotine products for 24 hours and given either a placebo or 50mg of naltrexone. At the end of each session, participants were given snacks with varying calorie levels, salt, sugar, and fat content.

 

As expected, a research group has found that participants who quit smoking tend to choose foods that are high in calories, salt, fat, and sugar. The study observed the involvement of receptors in the brain's opioid system in this behavior. The study shows that food choices and consumption are influenced by smoking status (abstinence > occasional smokers or non-smokers; p < .05), opioid antagonists (naltrexone < placebo; p < .05), and gender (males > females; p < .05). These effects were confirmed for high-sugar and high-fat foods, but no differences were found in low-sugar and low-fat foods.

 

Researchers have concluded that the use of food, particularly high-calorie food, is often employed as a coping mechanism for the negative effects and discomfort experienced by individuals during the process of quitting smoking.

 

(Source: Vaping Post)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former FDA Scientist Questions ZYN Review Over Pouch Material and Microplastic Risk
Former FDA Scientist Questions ZYN Review Over Pouch Material and Microplastic Risk
A former FDA toxicologist has questioned whether the agency fully assessed the material used in ZYN nicotine pouches before authorizing them for sale, raising concerns over possible microplastic exposure, according to STAT and The Examination.
Jul.16
Former ATF Official’s Claims on Chinese Vape Companies and 6-Methyl Nicotine Fuel US Regulatory Debate
Former ATF Official’s Claims on Chinese Vape Companies and 6-Methyl Nicotine Fuel US Regulatory Debate
Former ATF Deputy Director Edgar Domenech has warned that some Chinese vape companies may be using 6-methyl nicotine, a nicotine analogue, raising new questions over how US regulators should classify emerging nicotine compounds.
Jul.13
Product | Republic Technologies Launches ZIG Nicotine Pouches, Expanding Beyond Traditional Tobacco Accessories
Product | Republic Technologies Launches ZIG Nicotine Pouches, Expanding Beyond Traditional Tobacco Accessories
Republic Technologies UK has entered the nicotine pouch market with ZIG Nicotine Pouches, marking the company’s expansion beyond traditional tobacco-related accessories into smoke-free nicotine products. The product is expected to enter UK retail channels from August 2026, including convenience stores, supermarkets and tobacco retailers. The launch includes six flavors and three nicotine strengths: 8mg, 12mg and 17mg.
Market
Jul.21 by 2Firsts Perspectives
PMI Q2 Call: ZYN Growth, IQOS Pricing and a Diverging Global Tobacco Market
PMI Q2 Call: ZYN Growth, IQOS Pricing and a Diverging Global Tobacco Market
Philip Morris International’s second-quarter earnings call offered new detail on its smoke-free strategy. Management said it would increase U.S. investment behind nicotine pouch brand ZYN, keep IQOS focused on volume before stronger pricing, and use SENTIA, DELIA, LEVIA, VEEV and ZYN to manage tax and regulatory pressure across Japan and Europe. Analysts from Goldman Sachs, Morgan Stanley, UBS and other firms also pressed PMI on profitability, market share, cigarette resilience and the durability of its global transformation over coming quarters.
Jul.24
PMI Partners With Italian Tenor Andrea Bocelli to Launch “Believe. Further” Platform
PMI Partners With Italian Tenor Andrea Bocelli to Launch “Believe. Further” Platform
Philip Morris International (PMI) and Italian tenor Andrea Bocelli have launched “Believe. Further,” a multi-year communications platform targeting cultural, institutional and business audiences in Europe, as PMI says smoke-free products accounted for 43% of its net revenues as of the first quarter of 2026.
Jul.01
Product | PMI Introduces VEEV inPrime, Bringing an Induction Vaporization Platform to the Next Generation of the VEEV Portfolio
Product | PMI Introduces VEEV inPrime, Bringing an Induction Vaporization Platform to the Next Generation of the VEEV Portfolio
Philip Morris International (PMI) has introduced VEEV inPrime, the next-generation closed-system vape platform featuring the new AdvanceVape Induction System™. Alongside the new induction platform, PMI has redesigned the pods, e-liquid formulations and user interaction experience. According to PMI and official IQOS websites, VEEV inPrime began a phased European rollout between May and June 2026, with products now available in Greece, Estonia, the United Kingdom and Italy.
Jul.14